Biotech IV Monitor

NUVL — Nuvalent Inc.

Acquired by GSK · July 2026
Nuvalent Inc. was acquired by GSK in July 2026. NUVL no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to GSK, and their dates may not have been updated since.

Clinical trial readout dates for Nuvalent Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2027.

Next readoutDecember 2027in ~13 months
Upcoming readouts31 Phase 3

Upcoming readouts

Phase 1/2 Neladalkib (NVL-655)
Locally Advanced Solid Tumor; Metastatic Solid Tumor · NCT05384626
December 2027
Recruiting
Phase 1/2 Zidesamtinib (NVL-520)
Locally Advanced Solid Tumor; Metastatic Solid Tumor · NCT05118789
December 2027
Recruiting
Phase 3 Neladalkib (NVL-655)
Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive · NCT06765109
December 2029
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow NUVL, you can start the conversation.
Contact — questions or corrections about NUVL: dukeupt@gmail.com